The Source for Whistleblowers, Journalists, Legislators & Academics

Whistleblower Articles

Medicare Decides It Takes a Thief to Catch a Thief

With Medicare fraud costing the federal government an estimated $60 billion a year, it makes perfect sense that the Centers for Medicare and Medicaid Services has tapped aerospace innovator Northrop Grumman to create a predictive model that will detect fraud. Or does it? With all the great technology and healthcare companies out there, Northrop Grumman […]

Read more

Fraudsters lobby to muzzle whistleblowers Commentary: Corporations have proven they can’t police themselves

Last October, representatives from Pfizer Inc., Tyco International Ltd., Citigroup Inc. and other major companies met with officials from the Securities and Exchange Commission to share their views on rules implementing the Dodd-Frank whistleblower law. Not surprisingly, they want the rules watered down. What these companies have in common is that they each have been […]

Read more

FIRST PERSON: Don’t Muzzle the Whistleblowers

RIPPING OFF THE U.S. government has reached epidemic proportions. The Department of Justice estimates that fraud costs the Medicare system alone between $30-$60 billion annually. But instead of fines and jail time, fraudsters are frequently rewarded with more government business. And if the U.S. Chamber of Commerce and its allies have their way, these fraudsters […]

Read more

Pharmaceutical Regulation in the United States: A Confluence of Influences

Background Pharmaceuticals, like other consumer products distributed in the United States, are subject to regulation and scrutiny from multiple sources. Legislative oversight and statutory pronouncement, regulatory mandate and oversight, judicial review, and non-governmental organization (NGO) and media oversight directly and/or indirectly impact the conduct of pharmaceutical manufacturers. In addition, stakeholders including pharmaceutical company shareholders, employees […]

Read more

Corporate Integrity Agreements: Asking the Companies to Police Themselves, Please

I. Introduction The use of a corporate integrity agreements (“CIA”) in resolving the prosecution of pharmaceutical and medical companies is commonplace. As part of a deferred prosecution agreement, the U.S. Department of Justice, or the U.S. Department of Health and Human Services, Office of Inspector General, will ask the defendant corporation to enter into a […]

Read more

Changes to the False Claims Act in Senate Bill 386

Introduction Under new legislation, the federal False Claims Act (FCA),[1] will take an even more prominent role in protecting from fraud the increase of federal spending to meet the nation’s financial crisis.  With federal funds going to a range of projects– from state infrastructure “shovel ready” road building to Internet connectivity, green energy innovation and […]

Read more